Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $398,855.04 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Bryan Supran sold 1,758 shares of the stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the sale, the executive vice president owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. The trade was a 12.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $224.53 on Friday. The firm has a market cap of $30.04 billion, a PE ratio of 41.73 and a beta of 0.28. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. The stock has a 50-day moving average price of $238.05 and a 200-day moving average price of $277.78. Alnylam Pharmaceuticals, Inc. has a 1-year low of $197.81 and a 1-year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The company had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same quarter in the prior year, the company earned ($0.51) EPS. The firm’s revenue for the quarter was up 66.9% compared to the same quarter last year. As a group, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.71 earnings per share for the current year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors have recently modified their holdings of ALNY. SCS Capital Management LLC bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $34,784,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $50,773,000. Silvant Capital Management LLC bought a new position in shares of Alnylam Pharmaceuticals in the second quarter valued at approximately $5,456,000. Hsbc Holdings PLC boosted its position in shares of Alnylam Pharmaceuticals by 22.6% during the fourth quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock valued at $35,675,000 after buying an additional 16,503 shares during the last quarter. Finally, Keystone Investors PTE Ltd. purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $3,531,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Stifel Nicolaus reduced their price objective on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Morgan Stanley cut their target price on shares of Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating on the stock in a research note on Friday, July 31st. Bank of America cut their target price on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a research note on Tuesday, July 14th. Truist Financial decreased their price target on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. Finally, Royal Bank Of Canada dropped their price objective on shares of Alnylam Pharmaceuticals from $350.00 to $345.00 and set an “outperform” rating on the stock in a report on Thursday. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $366.65.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi), a biological process that can selectively reduce the production of disease-causing proteins. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include ONPATTRO (patisiran), an RNAi therapy for hereditary transthyretin-mediated amyloidosis with polyneuropathy; GIVLAARI (givosiran), for acute hepatic porphyria; OXLUMO (lumasiran), for primary hyperoxaluria type 1; and AMVUTTRA (vutrisiran), for transthyretin-mediated amyloidosis.